Droplet digital PCR for quantification of ITGA6 in a stool mRNA assay for the detection of colorectal cancers

World Journal of Gastroenterology

Volumn 23, Issue 16, 2017, Pages 2891-2898

  Herring, Elizabeth ^a   Kanaoka, Shigeru ^b   Tremblay, Éric ^a   Beaulieu, Jean François ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b HAMAMATSU MEDICAL CENTER   (Japan)

Author keywords

Advanced adenoma; Biomarker; Colorectal cancer; MRNA; Non invasive screening

Indexed keywords

ALPHA6 INTEGRIN; COMPLEMENTARY DNA; INTEGRIN ALPHA 6A; MESSENGER RNA; UNCLASSIFIED DRUG; ITGA6 PROTEIN, HUMAN; RNA; TUMOR MARKER;

ADVANCED CANCER; ANALYTICAL EQUIPMENT; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER SCREENING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DROPLET DIGITAL POLYMERASE CHAIN REACTION; FECES ANALYSIS; FECES LEVEL; GENE EXPRESSION ASSAY; GENERATOR; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION SYSTEM; PREDICTION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; TAQMAN DUPLEX ASSAY; TAQMAN DUPLEX ASSAY KIT; ADENOMA; CANCER STAGING; CASE CONTROL STUDY; CHEMISTRY; COLORECTAL TUMOR; FECES; GENETICS; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY;

ADENOMA; AREA UNDER CURVE; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FECES; HUMANS; INTEGRIN ALPHA6; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; RNA, NEOPLASM; ROC CURVE;

EID: 85018961807     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i16.2891     Document Type: Article

References (36)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-30 [PMID: 26742998 DOI: 10.3322/caac.21332]
2. Maratt JK, Saini SD. Colorectal cancer screening in the 21st century: where do we go from here? Am J Manag Care 2015; 21: e447-e449 [PMID: 26295273]
3. Robertson DJ, Imperiale TF. Stool Testing for Colorectal Cancer Screening. Gastroenterology 2015; 149: 1286-1293 [PMID: 26033632 DOI: 10.1053/j.gastro.2015.05.045]
4. Willyard C. Screening: Early alert. Nature 2015; 521: S4-S5 [PMID: 25970456 DOI: 10.1038/521S4a]
5. Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93: 1115-1122 [PMID: 16804870 DOI: 10.1002/bjs.5349]
6. Schroy PC, Lal S, Glick JT, Robinson PA, Zamor P, Heeren TC. Patient preferences for colorectal cancer screening: how does stool DNA testing fare? Am J Manag Care 2007; 13: 393-400 [PMID: 17620034]
7. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT). Gut Liver 2014; 8: 117-130 [PMID: 24672652 DOI: 10.5009/gnl.2014.8.2.117]
8. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-169 [PMID: 19189905]
9. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014; 160: 171 [PMID: 24658694 DOI: 10.7326/M13-1484]
10. Hamaya Y, Yoshida K, Takai T, Ikuma M, Hishida A, Kanaoka S. Factors that contribute to faecal cyclooxygenase-2 mRNA expression in subjects with colorectal cancer. Br J Cancer 2010; 102: 916-921 [PMID: 20145612 DOI: 10.1038/sj.bjc.6605564]
11. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000; 31: 51-57 [PMID: 10665913]
12. Koga Y, Yasunaga M, Katayose S, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H, Matsumura Y. Improved recovery of exfoliated colonocytes from feces using newly developed immunomagnetic beads. Gastroenterol Res Pract 2008; 2008: 605273 [PMID: 19125182 DOI: 10.1155/2008/605273]
13. Rengucci C, De Maio G, Menghi M, Scarpi E, Guglielmo S, Fusaroli P, Caletti G, Saragoni L, Casadei Gardini A, Zoli W, Falcini F, Amadori D, Calistri D. Improved stool DNA integrity method for early colorectal cancer diagnosis. Cancer Epidemiol Biomarkers Prev 2014; 23: 2553-2560 [PMID: 25128402 DOI: 10.1158/1055-9965.EPI-14-0379]
14. Yu YJ, Majumdar AP, Nechvatal JM, Ram JL, Basson MD, Heilbrun LK, Kato I. Exfoliated cells in stool: a source for reverse transcription-PCR-based analysis of biomarkers of gastrointestinal cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 455-458 [PMID: 18268130 DOI: 10.1158/1055-9965.EPI-07-2515]
15. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 371: 187-188 [PMID: 25006736 DOI: 10.1056/NEJMc1405215]
16. Stauber J, Shaikh N, Ordiz MI, Tarr PI, Manary MJ. Droplet digital PCR quantifies host inflammatory transcripts in feces reliably and reproducibly. Cell Immunol 2016; 303: 43-49 [PMID: 27063479 DOI: 10.1016/j.cellimm.2016.03.007]
17. Reck M, Tomasch J, Deng Z, Jarek M, Husemann P, Wagner-Döbler I. Stool metatranscriptomics: A technical guideline for mRNA stabilisation and isolation. BMC Genomics 2015; 16: 494 [PMID: 26140923 DOI: 10.1186/s12864-015-1694-y]
18. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004; 127: 422-427 [PMID: 15300574]
19. Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, Sugimura H, Kajimura M, Hishida A. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2009; 18: 1888-1893 [PMID: 19505922 DOI: 10.1158/1055-9965. EPI-08-0937]
20. Beaulieu JF, Herring E, Kanaoka S, Tremblay É. Use of integrin alpha 6 transcripts in a stool mRNA assay for the detection of colorectal cancers at curable stages. Oncotarget 2016; 7: 14684-14692 [PMID: 26895101 DOI: 10.18632/oncotarget.7407]
21. Huggett JF, Whale A. Digital PCR as a novel technology and its potential implications for molecular diagnostics. Clin Chem 2013; 59: 1691-1693 [PMID: 24100808 DOI: 10.1373/clinchem.2013.214742]
22. Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods 2013; 10: 1003-1005 [PMID: 23995387 DOI: 10.1038/nmeth.2633]
23. Cao L, Cui X, Hu J, Li Z, Choi JR, Yang Q, Lin M, Ying Hui L, Xu F. Advances in digital polymerase chain reaction (dPCR) and its emerging biomedical applications. Biosens Bioelectron 2017; 90: 459-474 [PMID: 27818047 DOI: 10.1016/j.bios.2016.09.082]
24. Zec H, Shin DJ, Wang TH. Novel droplet platforms for the detection of disease biomarkers. Expert Rev Mol Diagn 2014; 14: 787-801 [PMID: 25109704 DOI: 10.1586/14737159.2014.945437]
25. Sedlak RH, Kuypers J, Jerome KR. A multiplexed droplet digital PCR assay performs better than qPCR on inhibition prone samples. Diagn Microbiol Infect Dis 2014; 80: 285-286 [PMID: 25277746 DOI: 10.1016/j.diagmicrobio.2014.09.004]
26. Dydensborg AB, Teller IC, Groulx JF, Basora N, Paré F, Herring E, Gauthier R, Jean D, Beaulieu JF. Integrin alpha6Bbeta4 inhibits colon cancer cell proliferation and c-Myc activity. BMC Cancer 2009; 9: 223 [PMID: 19586553 DOI: 10.1186/1471-2407-9-223]
27. Groulx JF, Giroux V, Beauséjour M, Boudjadi S, Basora N, Carrier JC, Beaulieu JF. Integrin α6A splice variant regulates proliferation and the Wnt/β-catenin pathway in human colorectal cancer cells. Carcinogenesis 2014; 35: 1217-1227 [PMID: 24403311 DOI: 10.1093/carcin/bgu006]
28. Ni H, Dydensborg AB, Herring FE, Basora N, Gagné D, Vachon PH, Beaulieu JF. Upregulation of a functional form of the beta4 integrin subunit in colorectal cancers correlates with c-Myc expression. Oncogene 2005; 24: 6820-6829 [PMID: 16007143]
29. Beaulieu JF. Integrin α6β4 in colorectal cancer. World J Gastrointest Pathophysiol 2010; 1: 3-11 [PMID: 21607137 DOI: 10.4291/wjgp.v1.i1.3]
30. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7: e51862 [PMID: 23251644 DOI: 10.1371/journal.pone.0051862]
31. Dydensborg AB, Teller IC, Basora N, Groulx JF, Auclair J, Francoeur C, Escaffit F, Paré F, Herring E, Ménard D, Beaulieu JF. Differential expression of the integrins alpha6Abeta4 and alpha6Bbeta4 along the crypt-villus axis in the human small intestine. Histochem Cell Biol 2009; 131: 531-536 [PMID: 19107504 DOI: 10.1007/s00418-008-0547-z]
32. Yang R, Paparini A, Monis P, Ryan U. Comparison of nextgeneration droplet digital PCR (ddPCR) with quantitative PCR (qPCR) for enumeration of Cryptosporidium oocysts in faecal samples. Int J Parasitol 2014; 44: 1105-1113 [PMID: 25229177 DOI: 10.1016/j.ijpara.2014.08.004]
33. Purcell RV, Pearson J, Frizelle FA, Keenan JI. Comparison of standard, quantitative and digital PCR in the detection of enterotoxigenic Bacteroides fragilis. Sci Rep 2016; 6: 34554 [PMID: 27686415 DOI: 10.1038/srep34554]
34. Tajadini M, Panjehpour M, Javanmard SH. Comparison of SYBR Green and TaqMan methods in quantitative real-time polymerase chain reaction analysis of four adenosine receptor subtypes. Adv Biomed Res 2014; 3: 85 [PMID: 24761393 DOI: 10.4103/2277-91 75.127998]
35. Huggett JF, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. Clin Chem 2015; 61: 79-88 [PMID: 25338683 DOI: 10.1373/clinchem.2014.221366]
36. Campomenosi P, Gini E, Noonan DM, Poli A, D'Antona P, Rotolo N, Dominioni L, Imperatori A. A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer. BMC Biotechnol 2016; 16: 60 [PMID: 27538962 DOI: 10.1186/s12896-016-0292-7]